Cargando…

Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board

OBJECTIVE: Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xavier, Camila B, Link, Rudinei, Abreu, Leonília, Bettoni, Fabiana, Marson, Fabiane, Galante, Pedro A F, Masotti, Cibele, Amano, Mariane T, de Molla, Vinicius, Camargo, Anamaria A, Asprino, Paula F, Sabbaga, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322129/ https://www.ncbi.nlm.nih.gov/pubmed/37159554 http://dx.doi.org/10.1093/oncolo/oyad105

Ejemplares similares

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
por: Kollipara, Revathi, et al.
Publicado: (2017)

Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer
por: Manogue, Charlotte, et al.
Publicado: (2018)

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy‐Refractory Testicular Tumors
por: Lian, Bijun, et al.
Publicado: (2019)

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
por: Valiakhmetova, Andge, et al.
Publicado: (2019)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery
por: Kato, Shumei, et al.
Publicado: (2021)

Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein‐Drug Docking
por: Yu, Nian, et al.
Publicado: (2021)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1‐Rearranged Non‐Small Cell Lung Cancer: A Case Report
por: Li, Juan, et al.
Publicado: (2021)

Novel SLC12A2‐ROS1 Fusion in Non‐Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next‐Generation Sequencing Assay
por: Rodríguez‐Antolín, Carlos, et al.
Publicado: (2021)

Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy
por: Nardi, Valentina, et al.
Publicado: (2022)

Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit
por: Dong, Sharlene, et al.
Publicado: (2022)

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review
por: Gim, Gahyun, et al.
Publicado: (2022)

KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management
por: Brodey, Alexandra, et al.
Publicado: (2022)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022)

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
por: Scarpetti, Lauren, et al.
Publicado: (2023)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Prolonged Survival of NUT Midline Carcinoma and Current Approaches to Treatment
por: Kaplan, Henry G, et al.
Publicado: (2023)

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer
por: Hunt, Allison L, et al.
Publicado: (2023)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023)

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
por: File, Danielle M., et al.
Publicado: (2020)

Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary
por: Martinez, Francisco, et al.
Publicado: (2021)

Infantile ZFTA Fusion–Positive Tumor of the Posterior Fossa: Molecular Tumor Board
por: Paulson, Vera A., et al.
Publicado: (2023)

Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
por: Hamdan, Diaddin, et al.
Publicado: (2023)

Longitudinal Molecular Analysis of Tumor Exome and Transcriptome to Evaluate Clonal Evolution and Identify Novel Therapeutic Targets in Thymoma
por: Nabel, Christopher S., et al.
Publicado: (2023)

Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment
por: Yoshida, Reiko, et al.
Publicado: (2022)

Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk
por: Murphy, Andrew J., et al.
Publicado: (2022)

The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation
por: Carpinetti, Paola, et al.
Publicado: (2015)

Durable Response to Nivolumab in a Patient With Hepatic Sarcomatoid Carcinoma: Evolutive Characterization of Genomic and Immunohistochemical PD-L1 Expression Findings
por: Queiroz, Marcello M., et al.
Publicado: (2022)

Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules
por: Schumm, Max A., et al.
Publicado: (2021)

TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias
por: Asprino, Paula Fontes, et al.
Publicado: (2017)

A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Patient perspectives on testing for clonal hematopoiesis of indeterminate potential
por: Sella, Tal, et al.
Publicado: (2022)

Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity
por: Feldkamp, Jasper David, et al.
Publicado: (2022)

Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease
por: Huang, Yi-Chun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s4mvtknnrur1gnd1ogjv3q6n7s